<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Algorithm of drug causality for epidermal necrolysis (ALDEN)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Algorithm of drug causality for epidermal necrolysis (ALDEN)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Algorithm of drug causality for epidermal necrolysis (ALDEN)</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup> <colgroup width="35%"></colgroup> <colgroup width="15%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Criterion</td> <td class="subtitle1">Values</td> <td class="subtitle1" colspan="2">Rules to apply</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Delay from initial drug component intake to onset of reaction (index day)</td> <td>Suggestive: +3</td> <td>From 5 to 28 days</td> <td class="divider_bottom" rowspan="6">–3 to 3</td> </tr> <tr> <td>Compatible: +2</td> <td>From 29 to 56 days</td> </tr> <tr> <td>Likely: +1</td> <td>From 1 to 4 days</td> </tr> <tr> <td>Unlikely: –1</td> <td>&gt;56 days</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Excluded: –3</td> <td>Drug started on or after the index day</td> </tr> <tr class="divider_bottom"> <td>In case of previous reaction to the same drug, only changes for: <ul class="none"> <li>Suggestive: +3, from 1 to 4 days</li> <li>Likely: +1, from 5 to 56 days</li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="3">Drug present in the body on index day</td> <td>Definite: 0</td> <td>Drug continued up to index day or stopped at a time point less than 5 times the elimination half-life* before the index day</td> <td class="divider_bottom" rowspan="3">–3 to 0</td> </tr> <tr> <td>Doubtful: –1</td> <td>Drug stopped at a time point prior to the index day by more than 5 times the elimination half-life* but liver or kidney function alterations or suspected drug interactions<sup>¶</sup> are present</td> </tr> <tr class="divider_bottom"> <td>Excluded: –3</td> <td>Drug stopped at a time point prior to the index day by more than 5 times the elimination half-life*, without liver or kidney function alterations or suspected drug interactions<sup>¶</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="5">Prechallenge/rechallenge</td> <td>Positive specific for disease and drug: 4</td> <td>SJS/TEN after use of same drug</td> <td class="divider_bottom" rowspan="5">–2 to 4</td> </tr> <tr> <td>Positive specific for disease or drug: 2</td> <td>SJS/TEN after use of similar<sup>Δ</sup> drug or other reaction with same drug</td> </tr> <tr> <td>Positive unspecific: 1</td> <td>Other reaction after use of similar<sup>Δ</sup> drug</td> </tr> <tr> <td>Not done/unknown: 0</td> <td>No known previous exposure to this drug</td> </tr> <tr class="divider_bottom"> <td>Negative: –2</td> <td>Exposure to this drug without any reaction (before or after reaction)</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Dechallenge</td> <td>Neutral: 0</td> <td>Drug stopped (or unknown)</td> <td class="divider_bottom" rowspan="2">–2 or 0</td> </tr> <tr class="divider_bottom"> <td>Negative: –2</td> <td>Drug continued without harm</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Type of drug (notoriety)</td> <td>Strongly associated: 3</td> <td>Drug of the "high-risk" list according to previous case-control studies</td> <td class="divider_bottom" rowspan="6">–1 to 3</td> </tr> <tr> <td>Associated: 2</td> <td>Drug with definite but lower risk according to previous case-control studies</td> </tr> <tr> <td>Suspected: 1</td> <td>Several previous reports, ambiguous epidemiology results (drug "under surveillance")</td> </tr> <tr> <td>Unknown: 0</td> <td>All other drugs including newly released ones</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Not suspected: –1</td> <td>No evidence of association from previous epidemiology study with sufficient number of exposed controls<sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td>Intermediate score = total of all previous criteria</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Other cause</td> <td class="divider_bottom" rowspan="2">Possible: –1</td> <td>Rank all drugs from highest to lowest intermediate score</td> <td class="divider_bottom" rowspan="2">–1</td> </tr> <tr class="divider_bottom"> <td>If at least 1 has an intermediate score &gt;3, subtract 1 point from the score of each of the other drugs taken by the patient (another cause is more likely)</td> </tr> <tr> <td colspan="4"><strong>Final score: –12 to 10</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd">The likelihood of a patient having SJS/TEN is based on the final score:
<ul class="decimal_heading">
<li>Score &lt;0 — Very unlikely</li>
<li>Score 0 to 1 — Unlikely</li>
<li>Score 2 to 3 — Possible</li>
<li>Score 4 to 5 — Probable</li>
<li>Score ≥6 — Very probable</li>
</ul></div><div class="graphic_footnotes"><p>SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; ATC: anatomical therapeutic chemical.</p>
<p>* Drug (or active metabolite) elimination half-life from serum and/or tissues (according to pharmacology textbooks), taking into account kidney function for drugs predominantly cleared by kidney and liver function for those with high hepatic clearance.</p>
<p>¶ Suspected interaction was considered when more than 5 drugs were present in a patient's body at the same time.</p>
Δ Similar drug = same ATC code up to the fourth level (chemical subgroups).</div><div class="graphic_reference">Reprinted by permission from Macmillan Publishers Ltd: Clinical Pharmacology and Therapeutics. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60. www.nature.com/cpt. Copyright © 2010.</div><div id="graphicVersion">Graphic 93517 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
